Optical imaging has become an indispensable tool in drug development. This technology, which includes bioluminescence imaging, fluorescence imaging (FLI), and near-infrared imaging (NIR), has significantly enriched our capacity to perform thorough biodistribution and molecular imaging studies, thereby facilitating a smoother transition from concept to clinic.